EG432502 Inhibitors
EG432502 inhibitors belong to a class of chemical compounds designed to selectively interact with and inhibit the activity of a specific target protein, designated as EG432502. These inhibitors are characterized by their ability to bind to the active or regulatory site of the protein, resulting in modulation of its biological function. Structurally, they can possess a range of chemical scaffolds, often featuring heterocyclic cores or aromatic systems that enhance binding affinity and specificity. Commonly, these inhibitors are optimized through medicinal chemistry techniques to improve their potency, selectivity, and binding kinetics. The functional groups on these molecules play crucial roles in establishing strong interactions with the active site residues of the target protein, such as hydrogen bonding, hydrophobic interactions, or π-π stacking. EG432502 inhibitors may exhibit varied physicochemical properties, which can influence their solubility, stability, and permeability, key attributes for their performance in biological assays.
From a biochemical perspective, these inhibitors are used as tools to probe the activity of EG432502 in various biological processes. By modulating the activity of this protein, researchers can better understand its role in cellular pathways and its interactions with other biomolecules. Inhibitors are typically evaluated for their selectivity to ensure that they do not inadvertently affect similar proteins or related enzymes, as off-target effects can obscure the interpretation of experimental results. The characterization of these inhibitors may involve techniques like crystallography to understand their binding modes, enzymatic assays to quantify inhibition potency, and various in vitro studies to assess their effects on the function of EG432502. The detailed structure-activity relationship (SAR) analysis provides insights into how specific molecular modifications impact the inhibitor's performance, guiding the design of more effective and selective compounds for further studies.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits Rpl6l indirectly by targeting the mTOR pathway. Rapamycin forms a complex with FKBP12, inhibiting mTORC1 activation. This disrupts protein translation machinery, leading to decreased expression of Rpl6l. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Directly inhibits Rpl6l by binding to DNA and preventing RNA synthesis. Actinomycin D intercalates into DNA, blocking transcription, and subsequently hindering the synthesis of Rpl6l mRNA and its subsequent translation. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
Inhibits Rpl6l through GSK-3β modulation. SB-216763 activates GSK-3β, promoting its interaction with Rpl6l. This phosphorylation leads to Rpl6l degradation via the proteasomal pathway, resulting in reduced protein levels. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Indirectly inhibits Rpl6l by inducing DNA damage. Cisplatin forms DNA adducts, triggering cell stress responses. This includes the activation of p53, which downregulates Rpl6l transcription, ultimately reducing its expression. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Targets Rpl6l indirectly through mTOR inhibition. Torin 1 inhibits both mTORC1 and mTORC2, disrupting the downstream signaling cascades. This results in translational repression and reduced expression of Rpl6l. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Acts as an indirect inhibitor of Rpl6l by targeting the PI3K/Akt/mTOR pathway. LY294002 inhibits PI3K, attenuating Akt/mTOR signaling. This hinders the translation machinery, resulting in decreased expression of Rpl6l. | ||||||
Puromycin dihydrochloride | 58-58-2 | sc-108071 sc-108071B sc-108071C sc-108071A | 25 mg 250 mg 1 g 50 mg | $42.00 $214.00 $832.00 $66.00 | 394 | |
Directly inhibits Rpl6l by premature chain termination during translation. Puromycin is incorporated into the growing peptide chain, leading to the release of incomplete polypeptides and inhibiting the synthesis of full-length Rpl6l. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Indirectly inhibits Rpl6l by interfering with nucleotide metabolism. 5-Fluorouracil disrupts RNA synthesis and processing, leading to nucleolar stress and subsequent downregulation of Rpl6l. | ||||||
GSK-J4 | 1373423-53-0 | sc-507551 | 100 mg | $1275.00 | ||
Inhibits Rpl6l through epigenetic modulation. GSK-J4 is a histone demethylase inhibitor, altering the chromatin landscape. This influences the accessibility of Rpl6l gene, leading to transcriptional repression and reduced protein levels. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Indirectly inhibits Rpl6l through PI3K pathway modulation. Wortmannin inhibits PI3K, disrupting downstream Akt/mTOR signaling. This results in translational repression and reduced expression of Rpl6l. | ||||||